Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Altered airway surfactant phospholipid composition and reduced lung function in asthma
Ist Teil von
Journal of applied physiology (1985), 2000-10, Vol.89 (4), p.1283-1292
Ort / Verlag
Bethesda, MD: Am Physiological Soc
Erscheinungsjahr
2000
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
Departments of 1 Child Health and 2 Medicine,
University of Southampton, Southampton SO16 6YD, United
Kingdom; 3 Department of Gynecology-Obstetrics, State
University of New York at Buffalo, Buffalo, New York 14222-2099;
and 4 MRC Immunochemistry Unit, Department of Biochemistry,
University of Oxford, Oxford OX1 3QU, United
Kingdom
Pulmonary surfactant in
bronchoalveolar lavage fluid (BALF) and induced sputum from
adults with stable asthma ( n = 36) and healthy controls
( n = 12) was analyzed for phospholipid and protein compositions and function. Asthmatic subjects were graded as mild, moderate, or severe. Phospholipid compositions of BALF and sputum from
control subjects were similar and characteristic of surfactant. For
asthmatic subjects, the proportion of dipalmitoyl phosphatidylcholine (16:0/16:0PC), the major phospholipid in surfactant, decreased in
sputum ( P < 0.05) but not in BALF. 1 In
BALF, mole percent 16:0/16:0PC correlated with surfactant function
measured in a capillary surfactometer, and sputum mole percent
16:0/16:0PC correlated with lung function (forced expiratory volume in
1 s). Neither surfactant protein A nor total protein concentration
in either BALF or sputum was altered in asthma. These results suggest
altered phospholipid composition and function of airway (sputum) but
not alveolar (BALF) surfactant in stable asthma. Such underlying
surfactant dysfunction may predispose asthmatic subjects to further
surfactant inhibition by proteins or aeroallergens in acute asthma
episodes and contribute to airway closure in asthma. Consequently,
administration of an appropriate therapeutic surfactant could provide
clinical benefit in asthma.
asthma; surfactant; phospholipid; mass spectrometry
*
S. M. Wright and P. M. Hockey contributed equally to the
experimental work presented in this paper.